About Denali Therapeutics Inc. (DNLI)

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

DNLI Key Statistics

DNLI Price Performance

Denali Therapeutics Inc. stock has returned -3.29% over the past day, -8.03% over the past week, +2.71% over the past month, and +8.78% over the past three months. The stock trades between a 52-week low of $10.57 and a high of $23.77.

DNLI Financial Fundamentals

Denali Therapeutics Inc. reports a return on equity (ROE) of -45.69%, operating margin of -4971.00%, profit margin of -3653.00%. The debt-to-equity ratio is 0.04. Current ratio stands at 9.16.

DNLI Earnings

Denali Therapeutics Inc.'s next earnings report is expected on 2026-05-11 (67 days away). The company has a +0.75% earnings beat rate with an average surprise of -0.55%. Earnings consistency is rated as "high".

DNLI Ownership

Institutional investors hold approximately +0.99% of DNLI shares across 10 institutions. Insider ownership is +0.09%. Insider sentiment is "bearish".

DNLI Short Interest

DNLI has a short interest of +9.67% of float with a short ratio (days to cover) of 7.9.

DNLI AI Analysis Signal

iGotFomo's AI-powered signal engine rates DNLI as "BUY" with MEDIUM confidence (score: 48/100). 9 signals are bullish, 1 are bearish, and 2 are neutral.